var data={"title":"Influenza virus vaccine (live attenuated): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Influenza virus vaccine (live attenuated): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/55283?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=influenza-virus-vaccine-live-attenuated-drug-information\" class=\"drug drug_general\">see &quot;Influenza virus vaccine (live attenuated): Drug information&quot;</a> and <a href=\"topic.htm?path=influenza-virus-vaccine-live-attenuated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Influenza virus vaccine (live attenuated): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338609\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=12941\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=12941\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza New Recommendations</span>\n      <span class=\"collapsible-date\">August 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is recommending that core requirements for influenza immunization remain the same for the 2017&ndash;2018 flu season. The Advisory Committee on Immunization Practices (ACIP) is also recommending that any licensed, recommended, and age-appropriate trivalent or quadrivalent inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) be allowed for pregnant women. The previous recommendation specified use of IIV for pregnant women. ACIP reiterated that the quadrivalent live attenuated influenza nasal spray vaccine (LAIV4) should not be used in any setting during the upcoming flu season. Afluria (IIV3) is now indicated for people 5 years and older (previously 9 years and older). The influenza vaccine strains approved for the 2017&ndash;2018 season in the US are:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Trivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">A/Michigan/45/2015 (H1N1) pdm09&ndash;like virus (updated)</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">A/Hong Kong/4801/2014 (H3N2)&ndash;like virus</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">B/Brisbane/60/2008&ndash;like virus (Victoria lineage)</p></li></ul></li>\n          <li>\n            <p style=\"text-indent:0em;\">Quadrivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">The 3 trivalent vaccines, plus B/Phuket/3073/2013&ndash;like virus (Yamagata lineage)</p></li></ul></li></ul></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560232\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>FluMist Quadrivalent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239606\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>FluMist Quadrivalent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047941\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Live (Viral)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Live/Attenuated</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047934\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=influenza-virus-vaccine-live-attenuated-drug-information\" class=\"drug drug_general\">see &quot;Influenza virus vaccine (live attenuated): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>: Although live attenuated influenza vaccine (LAIV4) is FDA approved for healthy nonpregnant persons aged 2 to 49 years, the ACIP recommends LAIV4 not be used for any population for the 2017-18 season due to concerns regarding low effectiveness during the 2013-14 and 2015-16 seasons. Alternative products are available for certain patient populations: Persons &ge;6 months may receive the trivalent inactivated influenza vaccine (IIV3) or the quadrivalent inactivated influenza vaccine (IIV4) and persons &ge;18 years may receive vaccination with the recombinant influenza vaccine (RIV) (CDC/ACIP [Grohskopf 2017]). According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer vaccine prior to exposure to influenza. It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (and, if possible, by the end of October) and prior to onset of influenza activity in the community; however, vaccination should continue throughout the influenza season as long as vaccine is available (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Pediatric: <b>Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> In patients &lt;9 years, the number of doses needed per flu season is dependent upon vaccination history (see below) (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A single dose is needed if the patient received &ge;2 doses of trivalent or quadrivalent influenza vaccine prior to July 1 preceding the current flu season start. The two doses need not have been received during the same season or consecutive seasons.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Two doses are needed (separated by &ge;4 weeks) if any of the following:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patient received &le;1 dose of trivalent or quadrivalent influenza vaccine prior to July 1 peceding the current flu season start (including no previous vaccination)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; If vaccination status cannot be determined</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 8 years: Intranasal: 0.2 mL per dose (half dose per nostril); 1 or 2 doses per season, dependent upon vaccination history (see <b>Note</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 9 to 18 years: Intranasal: 0.2 mL per dose (half dose per nostril) (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Immunization:</b> Adults &le;49 years: Intranasal: 0.2 mL per dose (0.1 mL per nostril) (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560249\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FluMist Quadrivalent:  (1 ea) [contains egg white (egg protein), gelatin (pork)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560334\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734117\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.html&amp;token=uIdEtZ9z39AgWlT5ryl91EGHwZUw1ctyPVA6KzfXm1q2PXOjrUxHee+2owCOlPHzKQ6t6D+tnoJWCkI/Q6Cp0K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=12941\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047944\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intranasal: For intranasal administration only; do not inject. Administer 0.1 mL (half of the dose from a single sprayer) into each nostril while the recipient is in an upright position. Place the tip of the sprayer inside the nostril and depress plunger as rapidly as possible to deliver the dose. Remove dose divider clip and repeat into opposite nostril. The patient does not need to inhale during administration (may breathe normally). If recipient sneezes following administration, the dose should not be repeated (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">US law requires that the date of administration, name of the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address and documentation of the vaccine information statement (VIS; date on VIS, and date given to patient) be entered into the patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560246\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store in refrigerator at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F). <b>Do not freeze</b>; protect from light. The cold chain (2&deg;C to 8&deg;C [35&deg;F to 46&deg;F]) must be maintained when transporting intranasal influenza vaccine. The vaccine may be exposed to temperatures of up to 25&deg;C for up to 12 hours without adverse impact; return to refrigerator as soon as possible; only a single excursion outside of the recommended storage conditions is permitted. Once intranasal influenza vaccine has been administered, the sprayer should be disposed of according to the standard procedures for medical waste (eg, sharps or biohazard container).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047943\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine (FDA approved in ages 2 to 49 years)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine annual vaccination with seasonal influenza vaccine for all persons &ge;6 months who do not otherwise have contraindications to vaccination. Although live attenuated influenza vaccine (LAIV4) is FDA approved for healthy nonpregnant persons aged 2 to 49 years, the ACIP recommends LAIV4 not be used for any population for the 2017-18 season due to concerns regarding low effectiveness during the 2013-14 and 2015-16 seasons. Alternative products are available for certain patient populations: Persons &ge;6 months may receive the trivalent inactivated influenza vaccine (IIV3) or the quadrivalent inactivated influenza vaccine (IIV4) and persons &ge;18 years may receive vaccination with the recombinant influenza vaccine (RIV) (CDC/ACIP [Grohskopf 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560333\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">FluMist may be confused with flumazenil</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560240\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Events reported within 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache (more common in adults), irritability (children), lethargy (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (children), decreased appetite (children), sore throat (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Fatigue (adults), myalgia (more common in adults), weakness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (adults), nasal congestion (more common in children), rhinorrhea (more common in children), sinusitis (adults), sneezing (children), wheezing (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, Bell's palsy, encephalitis (vaccine-associated), epistaxis, exacerbation of asthma, Guillain-Barre syndrome, hypersensitivity reaction, meningitis (including eosinophilic meningitis), pericarditis, subacute necrotizing encephalomyelopathy (Leigh syndrome exacerbation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560336\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe allergic reaction (eg, anaphylaxis) to any component of the vaccine, including egg protein, or to previous influenza vaccination; children and adolescents (2 to 17 years of age) receiving aspirin therapy or aspirin-containing therapy because of the association of Reye syndrome with aspirin and wild-type influenza infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note</b>: The ACIP and NACI do not consider an egg allergy to be a contraindication to influenza vaccination (CDC/ACIP [Grohskopf 2017]; NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600949\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma/wheezing: Children &lt;24 months of age had increased wheezing and hospitalizations following administration in clinical trials; use of the nasal spray is not approved in this age group. ACIP recommends not using LAIV in patients with chronic pulmonary disorders including asthma and children 2 to 4 years of age who have had asthma or wheezing episodes within the past year. Use with caution in patients &gt;5 years of age who have asthma (CDC/ACIP [Grohskopf 2017]). Risk of wheezing following vaccination is increased in children &lt;5 years of age with a history of recurrent wheezing and in persons of any age with asthma. Patients with severe asthma or active wheezing were not included in clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disorders: ACIP does not recommend the use of LAIV in patients with chronic disorders of the cardiovascular system (except isolated hypertension) (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Medical conditions predisposing to influenza complications: Safety of LAIV in patients with medical conditions predisposing to influenza complications has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). Based on limited data, the benefits of vaccinating persons with a history of GBS who are also at high risk for complications of influenza, may outweigh the risks (CDC/ACIP [Grohskopf 2017]). Recent studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: ACIP does not recommend the use of LAIV in patients with HIV (CDC/ACIP, [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nasal congestion: Use another influenza vaccine or defer immunization with LAIV if nasal congestion is present which may impede delivery of vaccine (CDC/ACIP [Grohskopf 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral influenza antiviral medications: Live influenza virus vaccine (LAIV) should not be given until 48 hours after the completion of influenza antiviral therapy (influenza A and B). Influenza antiviral therapy (influenza A and B) should not be administered for 2 weeks after receiving LAIV. If influenza antiviral therapy (influenza A and B) and LAIV are administered concomitantly, revaccination should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adults: The safety and efficacy of the nasal spray have not been established in adults &ge;50 years of age (US labeling) or &ge;60 years of age (Canadian labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Due to association of Reye syndrome with aspirin, use of LAIV is contraindicated in pediatric patients on concurrent aspirin therapy; aspirin-containing products should be avoided for 4 weeks following vaccination in children and adolescents &le;17 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Data on the use of LAIV in immunocompromised patients is limited. <b>Avoid contact with severely immunocompromised individuals for at least 7 days following vaccination (at least 14 days per Canadian labeling).</b> ACIP does not recommend the use of LAIV in immunosuppressed patients (CDC/ACIP [Grohskopf 2017]). ACIP does not recommend the use of LAIV for persons who care for severely immunocompromised individuals who require a protective environment due to the theoretical risk of transmitting the live virus from the vaccine. Persons who care for the severely immunocompromised should receive either IIV or RIV (CDC/ACIP [Grohskopf 2017]). Live vaccines should be administered &ge;4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2017]; (IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnant women: ACIP and NACI do not recommend the use of LAIV in pregnant women (CDC/ACIP [Grohskopf 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arginine: Manufactured using arginine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chicken egg protein: Manufactured with chicken egg protein. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the ACIP and NACI regarding influenza vaccination to persons who report egg allergies; however, ACIP states a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination. Per ACIP, patients with a history of egg allergy who have experienced only hives following egg exposure should receive influenza vaccine if otherwise appropriate. Patients with a history of egg allergy other than hives (eg, angioedema, respiratory distress) should receive influenza vaccine if otherwise appropriate and administered in an inpatient or outpatient medical setting with health care supervision able to recognize and manage severe allergic conditions (CDC/ACIP [Grohskopf 2017]). However, AAP, American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology (ACAAI), and NACI state that patients may receive vaccination regardless of severity of egg allergy and no special precautions are required (AAP 2017; Greenhawt 2018; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gelatin: Manufactured using gelatin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gentamicin: Manufactured with gentamicin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: The safety of LAIV has not been established in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection. Use of the influenza vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Adult Immunization Schedule (ACIP [Kim 2017]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used (CDC/ACIP [Grohskopf 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299520\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600965\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12941&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiviral Agents (Influenza A and B): May diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated). Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Influenza Virus Vaccine (Live/Attenuated) may enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600944\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600945\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">LAIV is not recommended for use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Influenza vaccination with any licensed, recommended, age-appropriate vaccine is recommended for all women who are or may become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine. Although LAIV4 is approved for healthy nonpregnant persons aged 2 to 49 years, the ACIP recommends that LAIV4 not be used for any population for the 2017-2018 season and contraindicates use in pregnant women (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The nasal vaccine contains the same strains of influenza A and B found in the injection. Information specific to the use of LAIV in pregnancy is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600966\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The vaccine contains live attenuated viruses which infect and replicate within the cells lining the nasopharynx. Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the US Public Health Service. Preparations from previous seasons must not be used. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600968\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Most adults have antibody protection within 2 weeks of vaccination (CDC/ACIP [Grohskopf 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &ge;6 to 8 months when vaccine is antigenically similar to circulating virus (CDC/ACIP [Grohskopf 2016]); response may be diminished in persons &ge;65 years and limited evidence suggests titers may decline significantly 6 months following vaccination in this population (CDC/ACIP [Grohskopf 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Following nasal administration, vaccine is distributed in the nasal cavity (~90%), stomach (~3%), brain (~2%), and lung (0.4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10278555\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Seasonal quadrivalent influenza vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When vaccine supply is limited, target groups for influenza vaccination (those at higher risk of complications from influenza infection and their close contacts) include the following (CDC/ACIP [Grohskopf 2017]): <b>Note:</b> Only use LAIV if appropriate:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; All Infants and Children 6 to 59 months of age</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Persons &ge;50 years of age</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Residents of nursing homes and other long-term care facilities</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Adults and children with chronic pulmonary disorders (including asthma) or cardiovascular systems disorders (except hypertension), renal, hepatic, neurologic, or metabolic disorders (including diabetes mellitus)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Persons who have immunosuppression (including immunosuppression caused by medications or HIV)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Infants, children, and adolescents (6 months to 18 years of age) who are receiving long-term aspirin therapy, and therefore, may be at risk for developing Reye syndrome after influenza</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Women who are or will be pregnant during the influenza season</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Health care personnel</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Household contacts (including children) and caregivers of neonates, infants, and children &lt;5 years (particularly children &lt;6 months) and adults &ge;50 years</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Household contacts (including children) and caregivers of persons with medical conditions which put them at high risk of complications from influenza infection</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; American Indians/Alaska Natives</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Morbidly obese (BMI &ge;40)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939558\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>FluMist (IL, KR);</li>\n      <li>FluMist Quadrivalent (AU, GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). <i>Clin Infect Dis</i>. 2004;38(5):760-762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/14986264/pubmed\" target=\"_blank\" id=\"14986264\">14986264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashkenazi S, Vertruyen A, Arisegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. <i>Pediatr Infect Dis J</i>. 2006;25(10):870-879.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/17006279/pubmed\" target=\"_blank\" id=\"17006279\">17006279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/23580737/pubmed\" target=\"_blank\" id=\"23580737\">23580737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belshe RB, Mendelman PM, Treanor J, et al, &quot;The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine in Children,&quot; <i>N Engl J Med</i>, 1998, 338(20):1405-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/9580647/pubmed\" target=\"_blank\" id=\"9580647\">9580647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FluMist Quadrivalent (influenza virus vacine [live/attenuated]) [prescribing information]. Gaithersburg, MD: MedImmune, LLC; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barr&eacute; syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/23840621/pubmed\" target=\"_blank\" id=\"23840621\">23840621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. <i>MMWR Recomm Rep</i>. 2017;66(2):1-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/28841201/pubmed\" target=\"_blank\" id=\"28841201\">28841201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barr&eacute; syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infecti Dis</i>. 2013;13(9):769-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/23810252/pubmed\" target=\"_blank\" id=\"23810252\">23810252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2014-2015. Public Health Agency of Canada website. http://www.phac-aspc.gc.ca/naci-ccni/flu-grippe-eng.php. Published July 2014. Accessed September 17, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. <i>Pediatrics</i>. 2005;116(3):e397-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/16140685/pubmed\" target=\"_blank\" id=\"16140685\">16140685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. <i>Pediatrics</i>. 2002;110(4):662-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/12359778/pubmed\" target=\"_blank\" id=\"12359778\">12359778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rasmussen SA, Jamieson DJ, and Bresee JS, &quot;Pandemic Influenza and Pregnant Women,&quot; <i>Emerg Infect Dis</i>, 2008, 14(1):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/18258087/pubmed\" target=\"_blank\" id=\"18258087\">18258087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. <i>N Engl J Med</i>. 2008;9(15):1555-1564.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-live-attenuated-pediatric-drug-information/abstract-text/18799552/pubmed\" target=\"_blank\" id=\"18799552\">18799552</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12941 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50338609\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9560232\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11239606\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047941\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047934\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9560249\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9560334\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734117\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047944\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9560246\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047943\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9560333\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9560240\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9560336\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9600949\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299520\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9600965\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9600944\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9600945\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9600966\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9600968\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10278555\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939558\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12941|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=influenza-virus-vaccine-live-attenuated-drug-information\" class=\"drug drug_general\">Influenza virus vaccine (live attenuated): Drug information</a></li><li><a href=\"topic.htm?path=influenza-virus-vaccine-live-attenuated-patient-drug-information\" class=\"drug drug_patient\">Influenza virus vaccine (live attenuated): Patient drug information \t</a></li></ul></div></div>","javascript":null}